Yupelri (Revefenacin) for COPD: Dosing, Administration, and Safety
Yupelri (revefenacin) 175 mcg should be administered once daily via standard jet nebulizer with a mouthpiece for maintenance treatment of COPD patients. 1
Recommended Dose and Administration
The FDA-approved dose is 175 mcg (one 3 mL unit-dose vial) administered once daily by oral inhalation via nebulizer. 1
Administration Requirements:
- Use a standard jet nebulizer connected to an air compressor with a mouthpiece (NOT a face mask)
- Clinical trials established safety and efficacy using the PARI LC® Sprint nebulizer with PARI Trek® S compressor 1
- Non-compressor based nebulizer systems have NOT been studied and should be avoided
- Open the vial immediately before use - remove from foil pouch only when ready to administer
- Discard the vial and any residual content after each use 1
Critical Administration Warnings:
- Do NOT swallow Yupelri - for oral inhalation only 1
- Do NOT mix with other drugs in the nebulizer - compatibility has not been established 1
- No dosage adjustment needed for elderly patients or those with renal impairment 1
Safety Considerations and Contraindications
Absolute Contraindication:
Hypersensitivity to revefenacin or any component 1
Key Safety Warnings:
1. NOT for Acute Symptoms:
- Do NOT initiate during acute COPD exacerbations or deteriorating disease 1
- This is maintenance therapy only - NOT rescue therapy
- Use short-acting beta2-agonists for acute bronchospasm 1
2. Paradoxical Bronchospasm:
- If this occurs, discontinue immediately and use alternative therapy 1
3. Anticholinergic Effects - Use with Caution:
- Narrow-angle glaucoma: May worsen; instruct patients to report eye pain, blurred vision, or visual halos immediately 1
- Urinary retention: Use cautiously in prostatic hyperplasia or bladder-neck obstruction; patients should report difficulty urinating 1
4. Drug Interactions:
- Avoid concomitant anticholinergic medications - additive effects may occur 1
- Avoid OATP1B1 and OATP1B3 inhibitors (rifampicin, cyclosporine) - these increase active metabolite exposure 1
5. Hepatic Impairment:
- Avoid use in patients with hepatic impairment 1
Clinical Efficacy Evidence
Research demonstrates that revefenacin 175 mcg provides sustained bronchodilation over 52 weeks with significant improvements in trough FEV1 (52-124 mL improvement from baseline) 2. The drug shows comparable efficacy whether patients are taking concomitant long-acting beta-agonists with or without inhaled corticosteroids 2.
Deposition studies using functional respiratory imaging show revefenacin via nebulizer achieves three-fold higher intrathoracic and peripheral lung deposition compared to tiotropium via dry powder inhaler (34.6% vs 10.9% of delivered dose), making it particularly effective for patients with severe COPD 3.
Safety Profile
Meta-analysis of randomized controlled trials confirms revefenacin 175 mcg is well-tolerated with no significant differences versus placebo in discontinuation rates, adverse events, or serious adverse events 4. The most common adverse events are COPD worsening/exacerbation, cough, nasopharyngitis, upper respiratory tract infection, headache, and back pain 1, 4.
Importantly, minimal anticholinergic systemic effects were reported in clinical trials 5, and cardiovascular adverse events showed no significant increase versus placebo 4.
Clinical Context
While older COPD guidelines 6, 7, 8 establish that long-acting muscarinic antagonists are superior to placebo and short-acting bronchodilators for preventing COPD exacerbations, revefenacin represents the first and only once-daily LAMA approved for nebulized delivery 9, 10. This provides a critical option for patients who cannot properly use handheld inhalers due to severe disease, cognitive impairment, arthritis, or patient preference 9, 10.
The 2023 Canadian Thoracic Society guideline 11 strongly recommends long-acting bronchodilator maintenance therapy for all symptomatic COPD patients, supporting revefenacin's role in this treatment paradigm when nebulized delivery is preferred or required.